TCGA-A8-A09A-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 10
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.450
- PROTEIN_SECRETION+0.410
- UV_RESPONSE_DN+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- MITOTIC_SPINDLE+0.330
- ANDROGEN_RESPONSE+0.300
- TGF_BETA_SIGNALING+0.300
- APICAL_JUNCTION+0.260
- WNT_BETA_CATENIN_SIGNALING+0.260
- ESTROGEN_RESPONSE_EARLY+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.420
- MYC_TARGETS_V2-0.390
- E2F_TARGETS-0.340
- TNFA_SIGNALING_VIA_NFKB-0.310
- INTERFERON_GAMMA_RESPONSE-0.280
- PANCREAS_BETA_CELLS-0.270
- HYPOXIA-0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- DNA_REPAIR-0.240
- MYC_TARGETS_V1-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AN-A0XL-01A-11R-A10J-07 | — | A | 0.784 |
| 2 | 5b6bd2fd-de8e-4d58-9b38-c3b2bf2ed418 | — | — | 0.778 |
| 3 | TCGA-AR-A24M-01A-11R-A169-07 | — | B | 0.772 |
| 4 | TCGA-91-6829-01A-21R-1858-07 | — | cohortA1 | 0.770 |
| 5 | TCGA-CR-7372-01A-11R-2016-07 | — | — | 0.769 |
| 6 | TCGA-AR-A24L-01A-11R-A169-07 | — | B | 0.767 |
| 7 | TCGA-D8-A1X8-01A-11R-A14M-07 | — | B | 0.751 |
| 8 | TCGA-AO-A0J5-01A-11R-A034-07 | — | A | 0.749 |
| 9 | TCGA-55-6642-01A-11R-1858-07 | — | cohortA3 | 0.737 |
| 10 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.734 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |